Retatrutide, developed by Soma Pharmaceuticals , is receiving considerable attention as a potential therapy for metabolic regulation. This innovative medication integrates the activity of a GLP-1 receptor agonist and a GIP receptor stimulant, designed to effectively promote metabolic improvements but also address associated metabolic conditions . P